torsemide has been researched along with Aura in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gramer, M; Kirchhoff, L; Löscher, W; Schmidt, R; Welzel, B | 1 |
| Gailus, B; Gericke, B; Hampel, P; Johne, M; Kaczmarek, E; Löscher, W; Römermann, K | 1 |
| Delarge, J; Dogné, JM; Lambert, DM; Masereel, B; Poupaert, JH | 1 |
3 other study(ies) available for torsemide and Aura
| Article | Year |
|---|---|
The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Topics: Animals; Asphyxia; Bumetanide; Diuretics; Epilepsy; Furosemide; Rats; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Torsemide | 2023 |
Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Topics: Animals; Anticonvulsants; Bumetanide; Drug Therapy, Combination; Epilepsy; Female; Mice; Phenobarbital; Pilocarpine; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Sulfanilamides; Torsemide; Treatment Outcome | 2021 |
Anticonvulsant activity of pyrid-3-yl-sulfonyl ureas and thioureas.
Topics: Animals; Anticonvulsants; Diuretics; Epilepsy; Male; Mice; Neuroprotective Agents; Seizures; Sulfonamides; Sulfonylurea Compounds; Thiourea; Torsemide | 1997 |